Last updated on September 2016

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes Mellitus | Type 2 | Diabetes Mellitus Types I and II
  • Age: 40 Years
  • Gender: Male or Female

Eligibility criteria:

  • Age ≥ 40 years old
  • Subjects with a diagnosis of diabetes, type 2 and HbA1c values of 7.5 – 11%
  • Stable diabetes treatment regimen for the past 3 months.
  • Subjects who present with at least one of the following cardiovascular histories:
    • Myocardial infarction (heart attack)
    • Stroke
    • Prior coronary artery bypass grafting or coronary stent
    • Congestive heart failure
    • Multiple cardiovascular risk factors including Age ≥ 55 years, diabetes duration of = 10 years, uncontrolled hypertension, current smoking, chronic kidney disease, or low HDL cholesterol

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.